Altamira Therapeutics Past Earnings Performance
Past criteria checks 0/6
Altamira Therapeutics's earnings have been declining at an average annual rate of -19.8%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 46.1% per year.
Key information
-19.8%
Earnings growth rate
28.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 46.1% |
| Return on equity | -112.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02Revenue & Expenses BreakdownBeta
How Altamira Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -7 | 3 | 3 |
| 30 Jun 23 | 0 | -24 | 4 | 6 |
| 31 Mar 23 | 0 | -25 | 5 | 7 |
| 31 Dec 22 | 0 | -19 | 3 | 2 |
| 30 Sep 22 | 0 | -23 | 7 | 7 |
| 30 Jun 22 | 0 | -19 | 8 | 7 |
| 31 Mar 22 | 0 | -18 | 7 | 7 |
| 31 Dec 21 | 0 | -7 | 4 | 2 |
| 30 Sep 21 | 0 | -15 | 5 | 6 |
| 30 Jun 21 | 0 | -12 | 4 | 5 |
| 31 Mar 21 | 0 | -10 | 3 | 4 |
| 31 Dec 20 | 0 | -8 | 3 | 3 |
| 30 Sep 20 | 0 | -7 | 3 | 3 |
| 30 Jun 20 | 0 | -6 | 3 | 3 |
| 31 Mar 20 | 0 | -6 | 3 | 3 |
| 31 Dec 19 | 0 | -7 | 4 | 3 |
| 30 Sep 19 | 0 | -9 | 4 | 2 |
| 30 Jun 19 | 0 | -10 | 5 | 3 |
| 31 Mar 19 | 0 | -12 | 4 | 4 |
| 31 Dec 18 | 0 | -11 | 4 | 7 |
| 30 Sep 18 | 0 | -12 | 5 | 11 |
| 30 Jun 18 | 0 | -15 | 5 | 13 |
| 31 Mar 18 | 0 | -18 | 5 | 16 |
| 31 Dec 17 | 0 | -24 | 5 | 19 |
| 30 Sep 17 | 0 | -25 | 5 | 20 |
| 30 Jun 17 | 0 | -27 | 5 | 22 |
| 31 Mar 17 | 0 | -30 | 6 | 25 |
| 31 Dec 16 | 0 | -31 | 6 | 25 |
| 30 Sep 16 | 0 | -31 | 5 | 25 |
| 30 Jun 16 | 0 | -28 | 5 | 25 |
| 31 Mar 16 | 0 | -31 | 5 | 26 |
| 31 Dec 15 | 0 | -30 | 4 | 26 |
| 30 Sep 15 | 0 | -28 | 4 | 25 |
| 30 Jun 15 | 0 | -26 | 4 | 24 |
| 31 Mar 15 | 0 | -20 | 4 | 20 |
| 31 Dec 14 | 0 | -18 | 5 | 18 |
| 30 Sep 14 | 0 | -18 | 4 | 16 |
| 30 Jun 14 | 0 | -19 | 3 | 15 |
| 31 Mar 14 | 0 | -19 | 3 | 15 |
Quality Earnings: CYTO is currently unprofitable.
Growing Profit Margin: CYTO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYTO is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.
Accelerating Growth: Unable to compare CYTO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYTO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: CYTO has a negative Return on Equity (-112.56%), as it is currently unprofitable.